Prestige Consumer Healthcare (NYSE:PBH) Hits New 52-Week Low – Should You Sell?

Prestige Consumer Healthcare Inc. (NYSE:PBH)’s share price hit a new 52-week low during trading on Thursday . The stock traded as low as $55.27 and last traded at $54.8020, with a volume of 53794 shares trading hands. The stock had previously closed at $57.68.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PBH. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Jefferies Financial Group dropped their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $76.50.

Prestige Consumer Healthcare Stock Performance

The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The stock has a fifty day moving average price of $64.42 and a 200-day moving average price of $62.85. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of 13.88, a price-to-earnings-growth ratio of 1.57 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The firm had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business’s quarterly revenue was down 2.4% on a year-over-year basis. During the same quarter last year, the business earned $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president directly owned 41,048 shares in the company, valued at $2,706,294.64. The trade was a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently bought and sold shares of the company. UMB Bank n.a. raised its stake in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $29,000. First Horizon Corp purchased a new position in Prestige Consumer Healthcare during the third quarter worth $32,000. Barrow Hanley Mewhinney & Strauss LLC increased its position in Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after buying an additional 283 shares in the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).